4-benzhydrylidene-1-benzyl-piperidine | 13511-55-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-benzhydrylidene-1-benzyl-piperidine
• 英文别名: N-Benzyl-4-benzhydryliden-piperidin；4-Benzhydrylidene-1-benzylpiperidine
• CAS: 13511-55-2
• 化学式: C₂₅H₂₅N
• 分子量: 339.48
• InChiKey: MTYPZYPJOJRYCY-UHFFFAOYSA-N

物化性质

• 沸点：
  488.1±14.0 °C(Predicted)
• 密度：
  1.094±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  α,α-diphenyl-1-(phenylmethyl)-4-piperidinemethanol 在 硫酸 作用下， 反应 1.5h， 生成 4-benzhydrylidene-1-benzyl-piperidine
  参考文献：
  名称：

  Benzylpiperazine Derivatives. VII. Studies on the Role of the Nitrogen Atom in the Cerebral Vasodilating Activity of 1-Benzyl-4-diphenylmethylpiperazine Derivatives

  摘要：

  制备1-苄基-4-二苯基甲基哌啶衍生物以研究氮原子在其脑血管舒张活性中的作用。药理学测试结果表明，哌啶衍生物与我们的测试系统中的哌嗪衍生物大致等效。提出了结构-活性分析。

  DOI：

  10.1248/cpb.35.4637

文献信息

• N-(substituted arylmethyl)-4-(disubstituted methyl) piperidines and pyridines
  申请人：Ding Ping

  公开号：US20080090828A1

  公开（公告）日：2008-04-17

  It has now been found that certain novel N-(substituted aryl)-4-(disubstituted methyl)piperidine and pyridine derivatives have provided unexpected insecticidal activity. These compounds are represented by formula (I): wherein m, n, q, r, and s are independently selected from 0 or 1; and p is 0, 1, 2, or 3; A is C or CH; and B, D, E, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are fully described herein. In addition, compositions comprising an insecticidally effective amount of at least one compound of formula I, and optionally, an effective amount of at least one of a second compound, with at least one insecticidally compatible carrier are also disclosed; along with methods of controlling insects comprising applying said compositions to a locus where insects are present or are expected to be present.

  现在已经发现某些新型的N-(取代芳基)-4-(二取代甲基)哌啶和吡啶衍生物具有出乎意料的杀虫活性。这些化合物由式(I)表示：其中，m、n、q、r和s独立地选自0或1；p为0、1、2或3；A为C或CH；B、D、E、R、R1、R2、R3、R4、R5、R6、R7和R8在此完整描述。此外，还公开了包含式(I)中至少一种化合物的杀虫有效量，并且可选地包含第二种化合物的有效量，以及至少一种杀虫兼容载体的组合物；以及控制昆虫的方法，包括将所述组合物施用于昆虫存在或预计存在的地点。
• N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents
  申请人：A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation)

  公开号：EP0235463A2

  公开（公告）日：1987-09-09

  Cardiovascular disturbances and the effects of histamine and excessive gastric secretion can be countered by compounds expressed generally by the formula: wherein; p is zero, one or two; m is one to six inclusive; A is hydrogen, -O-R1, -C=N, -(O)NR1R2, -C(O)R1, -C(O)-OR1, -CH2OR1, -CH2NR1R2, or -OC(O)R1; Q is d and n are zero or one and the dotted lines represent double bonds which may form consistent with the valence of carbon; B is Ar, D and R are selected from phenyl and substituted phenyl with certain limitations, pyrldinyl, thienyl, furanyl or naphthyl and, in addition, R may have the values: benzyl, substituted benzyl, cycloalkyl or loweralkyl, and D may additionally have the values: 2H-1-benzopyran-2-one, 4-oxo-4H-1-benzopyran-2-carboxylic acid loweralkyl ester, 1,4-benzodioxanloweralkyl-2-yl or quinolinyl, and the pharmaceutically acceptable addition salts thereof.

  心血管紊乱以及组胺和胃液分泌过多的影响可由一般由式表示的化合物来抵消： 其中 p 为 0、1 或 2； m 是 1 至 6（包括 6）； A 是氢、-O-R1、-C=N、-(O)NR1R2、-C(O)R1、-C(O)-OR1、-CH2OR1、-CH2NR1R2 或 -OC(O)R1； Q 是 d 和 n 为 0 或 1，虚线表示可能形成的与碳价位一致的双键； B 是 Ar、D 和 R 选自苯基和有一定限制的取代苯基、吡啶基、噻吩基、呋喃基或萘基，此外，R 可具有以下值：苄基、取代苄基、环烷基或低级烷基，D 可具有以下值：2H-1-苯并吡喃-2-酮、4-氧代-4H-1-苯并吡喃-2-羧酸低级烷基酯、1,4-苯并二恶烷低级烷基-2-基或喹啉基，以及它们的药学上可接受的加成盐。
• DAJVA, MASATOSI;XASIGAKI, KUNIKO
  作者：DAJVA, MASATOSI、XASIGAKI, KUNIKO

  DOI：——

  日期：——
• METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER
  申请人：Haggerty Timothy J.

  公开号：US20140335050A1

  公开（公告）日：2014-11-13

  The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-β receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.
• US5070087A
  申请人：——

  公开号：US5070087A

  公开（公告）日：1991-12-03